Todos estos etf's y etn's son iguales, se invierte en algo que no tiene respaldo detrás. Es puro humo, hay que aprovecharlo para subir antes de que se desvanezca. Este tipo de productos en un mercado lógico no deberían existir
Pues vaya, eso de que esos etf's tienden a 0 porque se van quedando una parte no lo sabía.
Como dice Sietesoles no parece muy normal que dejen que existan este tipo de productos.
Gracias a los dos por esa información!
Esto es un casino, puedes ir un día y ganar pero si vas todos los días al final tu cuenta tiende a cero. Esos etf's referenciados son así, solo para especuladores, la inversión es un suicidio
Está bastante bien para enredar un poco echando un vistazo a las listas que pone. A la altura del gráfico de ADP están el resto de las listas.
The Price of Prevention: Vaccine Costs Are Soaring
Amplio articulo sobre el mercado de las vacunas
http://www.nytimes.com/2014/07/03/health/Vaccine-Costs-Soaring-Paying-Till-It-Hurts.html?_r=1
Whitehead Institute for Biomedical Research - CAMBRIDGE
HSP90 empowers evolution of resistance to hormonal therapy in human breast cancer models
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE61906
"... it dramatically impaired the emergence of resistance to hormone antagonists both in cell culture and in mice ..."
Resultados positivos en ratones.
Se que hay diferentes organizaciones trabajando de forma independiente con el compuesto de SNTA pero no tengo ni idea si esto son old news o es algo nuevo.
SNTA
Æterna Zentaris (NASDAQ: AEZS) and Sinopharm A-Think Pharmaceuticals Co., Ltd. announced the signing of an exclusive license and technology transfer agreement, for the Company's lead anti-cancer compound, zoptarelin doxorubicin, for the initial indication of endometrial cancer, for the Chinese, Hong Kong and Macau markets (the "Territory"). Zoptarelin doxorubicin, a novel synthetic peptide carrier linked to doxorubicin, is currently in a ZoptEC (Zoptarelin doxorubicin in Endometrial Cancer) Phase 3 trial in endometrial cancer.
Under the terms of the Master Collaboration Agreement, Aeterna Zentaris will be entitled to receive a non‑refundable $1 million fee for the transfer of the Company's technology for zoptarelin doxorubicin to SinopharmA-Think. SinopharmA-Think has also agreed to make additional payments to the Company upon achieving certain pre-established regulatory and commercial milestones. Furthermore, the Company will receive royalties on future net sales of zoptarelin doxorubicin in the Territory. SinopharmA-Think will be responsible for the development, production, registration and commercialization of the product in the Territory.
David Dodd, Chairman and CEO at Aeterna Zentaris stated, "We are very excited regarding this agreement for zoptarelin doxorubicin with Sinopharm, the largest pharmaceutical company in China, which is one of the major domestic markets in the world for pharmaceutical products. Women with advanced endometrial cancer are in need of additional treatments, and zoptarelin doxorubicin might prove to be a significant treatment option for them. This agreement is also consistent with our strategy of leveraging our pipeline to secure future revenues with strategic development and commercial licensees for specific regions of the world."
AEZS
